Tag: ReCell

June 2, 2020 Off

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

VALENCIA, Calif. & MELBOURNE, Australia–(BUSINESS WIRE)–AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform…

October 5, 2015 Off

Avita expands Compassionate Use IDE program for ReCell

By Dino Mustafić

FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.